Insider Selling: Concert Pharmaceuticals Inc (CNCE) Director Sells 31,236 Shares of Stock

Concert Pharmaceuticals Inc (NASDAQ:CNCE) Director Richard Aldrich sold 31,236 shares of the firm’s stock in a transaction dated Tuesday, January 16th. The shares were sold at an average price of $19.14, for a total value of $597,857.04. Following the completion of the sale, the director now directly owns 286,975 shares in the company, valued at $5,492,701.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Richard Aldrich also recently made the following trade(s):

  • On Thursday, February 1st, Richard Aldrich sold 11,946 shares of Concert Pharmaceuticals stock. The shares were sold at an average price of $20.89, for a total value of $249,551.94.
  • On Friday, January 26th, Richard Aldrich sold 5,000 shares of Concert Pharmaceuticals stock. The shares were sold at an average price of $20.46, for a total value of $102,300.00.
  • On Monday, January 29th, Richard Aldrich sold 18,054 shares of Concert Pharmaceuticals stock. The shares were sold at an average price of $20.63, for a total value of $372,454.02.
  • On Monday, January 22nd, Richard Aldrich sold 10,000 shares of Concert Pharmaceuticals stock. The shares were sold at an average price of $19.55, for a total value of $195,500.00.
  • On Wednesday, January 24th, Richard Aldrich sold 30,000 shares of Concert Pharmaceuticals stock. The shares were sold at an average price of $19.68, for a total value of $590,400.00.
  • On Friday, January 19th, Richard Aldrich sold 30,000 shares of Concert Pharmaceuticals stock. The shares were sold at an average price of $19.35, for a total value of $580,500.00.

Concert Pharmaceuticals Inc (NASDAQ CNCE) traded down $0.13 during midday trading on Monday, hitting $19.96. 263,848 shares of the company traded hands, compared to its average volume of 541,533. Concert Pharmaceuticals Inc has a twelve month low of $9.01 and a twelve month high of $30.71. The company has a market capitalization of $457.50, a PE ratio of 5.37 and a beta of 1.23.

Concert Pharmaceuticals (NASDAQ:CNCE) last released its earnings results on Thursday, November 9th. The biotechnology company reported ($0.70) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.54) by ($0.16). The company had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.02 million. Concert Pharmaceuticals had a net margin of 62.31% and a negative return on equity of 51.48%. research analysts predict that Concert Pharmaceuticals Inc will post 4.1 EPS for the current year.

Several equities research analysts have recently issued reports on CNCE shares. Stifel Nicolaus reaffirmed a “buy” rating and issued a $30.00 price target on shares of Concert Pharmaceuticals in a research report on Sunday, October 22nd. Mizuho reaffirmed a “hold” rating and issued a $23.00 price target on shares of Concert Pharmaceuticals in a research report on Thursday, February 1st. BidaskClub cut shares of Concert Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Friday, December 22nd. Zacks Investment Research cut shares of Concert Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, October 24th. Finally, HC Wainwright reiterated a “buy” rating and issued a $21.00 target price on shares of Concert Pharmaceuticals in a research note on Friday, November 10th. Three analysts have rated the stock with a hold rating and five have given a buy rating to the company. Concert Pharmaceuticals currently has an average rating of “Buy” and an average price target of $24.33.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. The Manufacturers Life Insurance Company lifted its stake in Concert Pharmaceuticals by 1.9% during the second quarter. The Manufacturers Life Insurance Company now owns 15,052 shares of the biotechnology company’s stock worth $210,000 after purchasing an additional 287 shares during the period. Rhumbline Advisers lifted its stake in Concert Pharmaceuticals by 8.0% during the second quarter. Rhumbline Advisers now owns 20,253 shares of the biotechnology company’s stock worth $283,000 after purchasing an additional 1,500 shares during the period. Bank of New York Mellon Corp lifted its stake in Concert Pharmaceuticals by 1.5% during the second quarter. Bank of New York Mellon Corp now owns 125,996 shares of the biotechnology company’s stock worth $1,757,000 after purchasing an additional 1,852 shares during the period. Alps Advisors Inc. lifted its stake in Concert Pharmaceuticals by 12.5% during the fourth quarter. Alps Advisors Inc. now owns 25,139 shares of the biotechnology company’s stock worth $650,000 after purchasing an additional 2,796 shares during the period. Finally, Teachers Advisors LLC lifted its stake in Concert Pharmaceuticals by 11.1% during the second quarter. Teachers Advisors LLC now owns 34,373 shares of the biotechnology company’s stock worth $480,000 after purchasing an additional 3,446 shares during the period. Hedge funds and other institutional investors own 67.44% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Insider Selling: Concert Pharmaceuticals Inc (CNCE) Director Sells 31,236 Shares of Stock” was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this news story on another domain, it was illegally copied and republished in violation of United States and international trademark & copyright law. The correct version of this news story can be read at https://www.dispatchtribunal.com/2018/02/12/concert-pharmaceuticals-inc-cnce-director-sells-597857-04-in-stock.html.

About Concert Pharmaceuticals

Concert Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others. The Company’s deuterated chemical entity platform (DCE Platform), has potential across various therapeutic areas.

Insider Buying and Selling by Quarter for Concert Pharmaceuticals (NASDAQ:CNCE)

Receive News & Ratings for Concert Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concert Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply